ERBB2 and gastric cancer: Its therapeutic potential in HER2-positive solid tumours is evident, as various iterations of this novel class of drug are being assessed at early phase level, and there are several clinical trials assessing HER2-directed ADCs specifically in gastric cancers (Table 2).